Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics.
Parkinson's disease (PD) is a movement disorder characterized by progressive degeneration of central dopaminergic systems. Current therapies designed to augment dopaminergic neurotransmission effectively treat the motoric aspects of the disease, however, with prolonged use, they produce a range of treatment-limiting side effects. Of these, neuropsychiatric abnormalities including hallucinosis and psychosis are common, disabling and refractory to most current therapies. This review describes the clinical syndrome of psychosis in PD and data regarding the efficacy and tolerability of existing antipsychotic agents, and presents the scientific rationale for the development of serotonin 2A receptor inverse agonists as potential therapeutic agents for treatment-induced psychosis of PD.
Weiner
David M
DM
ACADIA Pharmaceuticals Inc, 3911 Sorrento Valley Boulevard, San Diego, CA 92121, USA. dweiner@acadia-pharm.com
Vanover
Kimberly E
KE
Brann
Mark R
MR
Meltzer
Herbert Y
HY
Davis
Robert E
RE
D000818:Animals; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D011605:Psychoses, Substance-Induced / Q000188:drug therapy* / Q000523:psychology; D044402:Receptor, Serotonin, 5-HT2A / Q000502:physiology; D058826:Serotonin 5-HT2 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use*
D044402:Receptor, Serotonin, 5-HT2A; D058826:Serotonin 5-HT2 Receptor Agonists; D017366:Serotonin Receptor Agonists